Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/38361| Title: | Preliminary results of a phase 1A/1B study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb), in patients with advanced hepatocellular carcinoma (HCC). | Authors: | Qi Q.;Chao Y.;Hill A.;Kang J.;Wang L. ;Li K.;Gan H.;Wu Z.;Yen C.-J.;Markman B. | Institution: | (Yen) National Cheng Kung University Hospital, Tainan, Taiwan (Republic of China) (Markman) Monash Medical Centre, Clayton, Australia (Chao) Taipei Veterens General Hospital, Taipei City, Taiwan (Republic of China) (Hill) Tasman Oncology Research Ltd., Southport, Australia (Kang, Wang, Li, Qi) BeiGene (Beijing) Co. Ltd., Beijing, China (Wu) BeiGene USA Inc., Fort Lee, New Jersey, United States (Gan) Austin Hospital, Melbourne, Australia | Issue Date: | 3-Mar-2020 | Copyright year: | 2017 | Publisher: | Elsevier Ltd | Place of publication: | United Kingdom | Publication information: | Annals of Oncology. 28 (Supplement 3) (pp iii54), 2017. Date of Publication: June 2017. | Journal: | Annals of Oncology | DOI: | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1093/annonc/mdx261.139 | PubMed URL: | 32135938 [http://www.ncbi.nlm.nih.gov/pubmed/?term=32135938] | ISSN: | 0923-7534 | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/38361 | Type: | Article | Subjects: | response evaluation criteria in solid tumors upper respiratory tract infection sorafenib sorafenib/ct tislelizumab tislelizumab/ct advanced cancer antineoplastic activity ascites cancer control coughing decreased appetite drug dose escalation drug eruption drug fatality drug safety drug tolerability fatigue fever liver cell carcinoma phase 1 |
Type of Clinical Study or Trial: | Clinical trial |
| Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.